ChiRhoClin announced that the shortage of ChiRhoStim (human secretin for injection) has been resolved, after the company worked with the Food and Drug Administration (FDA), the Center for Drug Evaluation and Research (CDER), the Drug Shortage Team, and the Office of Pharmaceutical Quality (OPQ) to resolve the shortage.
The resolution of the ChiRhoStim shortage follows the approval of ChiRhoClin’s contract manufacturing facility to produce the drug for over a decade. Clinical trials and grant programs with ChiRhoStim will now be reinstated.
ChiRhoStim is indicated for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction; for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma; and for facilitation of the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP). ChiRhoStim injection is available as a lyophilized sterile powder in 16mcg and 40mcg vials.
For more information call (877) 272-4888 or visit ChiRhoStim.com.